Facility
The Solistaa facility is having 3500 sq.m area that has been utilised for manufacturing, quality control and administrative functions. The current facility has manufacturing and testing operations for gummies, liquids, tablets and capsules.
Dedicated Gummy manufacturing facility is operated under classified environmental conditions. There are separate area for manufacturing, drying, coating and packaging of gummies. Solistaa is in the process of automation in the packaging line.
The Solistaa uses only vegetarian source raw materials for gummy manufacturing. All raw materials and packing materials are tested in-house or by approved laboratories outside. All finished products are tested in-house including microbial analysis. All production operations are under ISO class 100,000 environmental conditions. Warehouse is fully air-conditioned with epoxy flooring.
The packaging facilities include bulk packing, Alu-Alu blister packing and PvC-Alu blister packing. Sophisticated instruments are available for instrumental and microbial testing. There is a full-fledged stability testing, as per the ICH requirements, facility available in-house.
Business Model
The business model of Solistaa is contract manufacturing through supply and quality agreement. Solistaa provides end to end solutions from formulation development to regulatory filing documentation. Based on the market requirements the product development is fine tuned.
Solistaa is currently working with various “Functional food ingredient” manufacturers under exclusivity for the development of various dosage forms under one roof.
The strength of Solistaa is to design a dosage form by combining multiple functional food ingredients and to position under different therapeutic segments. Solistaa has filed three “Food ingredients” (first time India) with Central FSSAI for obtaining approval to launch in India. All ingredients and additives will be fully regulatory compliant considering which market the products are getting launched and which type of consumers the products are going to cater.
For Indian market the ingredients and additives as approved by FSSAI will only be considered. The specifications of ingredients and additives will be in compliance with Codex Alimentarius or in-house specifications at the minimum. If customers are specific to have Pharmacopoeial (IP, BP, USP etc.) the same shall be agreed upon during the agreement stage to finalise the formulation development and stability testing, where required.